These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 31687889)

  • 41. Complement C3d/C4d Deposition on Platelets Correlates with 2'-O-Methoxyethyl Antisense Oligonucleotide-Induced Thrombocytopenia in Monkeys.
    Shen L; Wong A; Oneda S; Curtis BR; Schroeder J; Zanardi T; Engelhardt JA; Henry SP; Narayanan P
    Nucleic Acid Ther; 2023 Jun; 33(3):209-225. PubMed ID: 37093125
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Antisense oligonucleotides: target validation and development of systemically delivered therapeutic nanoparticles.
    Zhang C; Pei J; Kumar D; Sakabe I; Boudreau HE; Gokhale PC; Kasid UN
    Methods Mol Biol; 2007; 361():163-85. PubMed ID: 17172711
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impurity profiling of anticancer preclinical candidate, IIIM-290.
    Kumar V; Bhurta D; Sharma A; Kumar P; Bharate SB; Vishwakarma RA; Bharate SS
    J Pharm Biomed Anal; 2019 Mar; 166():1-5. PubMed ID: 30590350
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Materials in Manufacturing and Packaging Systems as Sources of Elemental Impurities in Packaged Drug Products: A Literature Review.
    Jenke DR; Stults CL; Paskiet DM; Ball DJ; Nagao LM
    PDA J Pharm Sci Technol; 2015 1/2; 69(1):1-48. PubMed ID: 25691713
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetic properties of 2'-O-(2-methoxyethyl)-modified oligonucleotide analogs in rats.
    Geary RS; Watanabe TA; Truong L; Freier S; Lesnik EA; Sioufi NB; Sasmor H; Manoharan M; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):890-7. PubMed ID: 11181921
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A facile one-step fluorescence method for the quantitation of low-content single base deamination impurity in synthetic oligonucleotides.
    Su X; Liang R; Stolee JA
    J Pharm Biomed Anal; 2018 Jun; 155():50-55. PubMed ID: 29614399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Antisense oligonucleotides for the treatment of dyslipidaemia.
    Visser ME; Witztum JL; Stroes ES; Kastelein JJ
    Eur Heart J; 2012 Jun; 33(12):1451-8. PubMed ID: 22634577
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A Risk-Based Approach to Evaluate and Control Elemental Impurities in Therapeutic Proteins.
    Luo Y; Sekhar C; Lee H; Fujimori K; Ronk M; Semin D; Nashed-Samuel Y
    J Pharm Sci; 2020 Nov; 109(11):3378-3385. PubMed ID: 32745562
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chemical profiling of the synthetic cannabinoid MDMB-CHMICA: Identification, assessment, and stability study of synthesis-related impurities in seized and synthesized samples.
    Münster-Müller S; Hansen S; Opatz T; Zimmermann R; Pütz M
    Drug Test Anal; 2019 Aug; 11(8):1192-1206. PubMed ID: 31124282
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Industrial approaches and consideration of clinical relevance in setting impurity level specification for drug substances and drug products.
    Pokar D; Rajput N; Sengupta P
    Int J Pharm; 2020 Feb; 576():119018. PubMed ID: 31911117
    [TBL] [Abstract][Full Text] [Related]  

  • 51. An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in mice.
    Bennett CF; Kornbrust D; Henry S; Stecker K; Howard R; Cooper S; Dutson S; Hall W; Jacoby HI
    J Pharmacol Exp Ther; 1997 Feb; 280(2):988-1000. PubMed ID: 9023316
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Drug impurities: problems and regulations.
    Pifferi G; Mannucci A
    Boll Chim Farm; 1999 Nov; 138(10):500-7. PubMed ID: 10765465
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Lack of QT Prolongation for 2'-O-Methoxyethyl-Modified Antisense Oligonucleotides Based on Retrospective Exposure/Response Analysis of Ten Phase 1 Dose-Escalation Placebo-Controlled Studies in Healthy Subjects.
    Yu RZ; Gunawan R; Geary RS; Hughes SG; Henry SP; Wang Y
    Nucleic Acid Ther; 2017 Oct; 27(5):285-294. PubMed ID: 28799823
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Synthesis and cellular activity of stereochemically-pure 2'-O-(2-methoxyethyl)-phosphorothioate oligonucleotides.
    Li M; Lightfoot HL; Halloy F; Malinowska AL; Berk C; Behera A; Schümperli D; Hall J
    Chem Commun (Camb); 2017 Jan; 53(3):541-544. PubMed ID: 27966701
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Local and systemic tolerability of a 2'O-methoxyethyl antisense oligonucleotide targeting interleukin-4 receptor-α delivery by inhalation in mouse and monkey.
    Fey RA; Templin MV; McDonald JD; Yu RZ; Hutt JA; Gigliotti AP; Henry SP; Reed MD
    Inhal Toxicol; 2014 Jul; 26(8):452-63. PubMed ID: 24932560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pharmacokinetics and pharmacodynamics of an antisense phosphorothioate oligonucleotide targeting Fas mRNA in mice.
    Yu RZ; Zhang H; Geary RS; Graham M; Masarjian L; Lemonidis K; Crooke R; Dean NM; Levin AA
    J Pharmacol Exp Ther; 2001 Feb; 296(2):388-95. PubMed ID: 11160622
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification, isolation and characterization of impurities of clindamycin palmitate hydrochloride.
    Bharathi Ch; Jayaram P; Sunder Raj J; Saravana Kumar M; Bhargavi V; Handa VK; Dandala R; Naidu A
    J Pharm Biomed Anal; 2008 Dec; 48(4):1211-8. PubMed ID: 18947955
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of Five Oxidative Degradation Impurities and One Process Impurity of Suvorexant Drug Substance by LC-MS/MS, HR-MS and 1D, 2D NMR: Validation of Suvorexant Drug Substance and Process Impurities by HPLC and UPLC.
    Rajana N; Devi DR; Kumar Reddy DN; Babu JM; Basavaiah K; Balakumaran K
    J Chromatogr Sci; 2020 Apr; 58(5):433-444. PubMed ID: 32134104
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Evaluation of C-5 propynyl pyrimidine-containing oligonucleotides in vitro and in vivo.
    Shen L; Siwkowski A; Wancewicz EV; Lesnik E; Butler M; Witchell D; Vasquez G; Ross B; Acevedo O; Inamati G; Sasmor H; Manoharan M; Monia BP
    Antisense Nucleic Acid Drug Dev; 2003; 13(3):129-42. PubMed ID: 12954113
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R; Morgan E; Watts L; Xia S; Hannan LA; Geary RS; Baker BF; Bhanot S
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.